[HLFG] YoY Annualized Quarter Result on 30-Sep-2016 [#1]

Announcement Date
22-Nov-2016
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2017
Quarter
30-Sep-2016 [#1]
Profit Trend
QoQ- 13.68%
YoY- -0.18%
View:
Show?
Annualized Quarter Result
30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 30/09/14 30/09/13 CAGR
Revenue 5,304,664 5,532,660 5,115,008 4,725,848 4,586,488 4,334,036 4,691,316 2.06%
PBT 3,654,596 3,716,424 3,361,844 2,902,056 2,787,916 2,987,972 3,250,304 1.97%
Tax -680,700 -637,996 -601,496 -568,616 -461,200 -620,476 -700,828 -0.48%
NP 2,973,896 3,078,428 2,760,348 2,333,440 2,326,716 2,367,496 2,549,476 2.59%
-
NP to SH 1,960,804 2,022,780 1,821,008 1,544,768 1,547,528 1,568,620 1,720,756 2.19%
-
Tax Rate 18.63% 17.17% 17.89% 19.59% 16.54% 20.77% 21.56% -
Total Cost 2,330,768 2,454,232 2,354,660 2,392,408 2,259,772 1,966,540 2,141,840 1.41%
-
Net Worth 19,498,958 18,182,568 17,109,476 15,916,059 13,787,257 11,806,591 10,457,863 10.93%
Dividend
30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 30/09/14 30/09/13 CAGR
Div 591,912 595,398 596,708 596,708 545,199 545,242 541,642 1.48%
Div Payout % 30.19% 29.43% 32.77% 38.63% 35.23% 34.76% 31.48% -
Equity
30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 30/09/14 30/09/13 CAGR
Net Worth 19,498,958 18,182,568 17,109,476 15,916,059 13,787,257 11,806,591 10,457,863 10.93%
NOSH 1,147,516 1,147,516 1,147,516 1,147,516 1,048,460 1,048,542 1,041,619 1.62%
Ratio Analysis
30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 30/09/14 30/09/13 CAGR
NP Margin 56.06% 55.64% 53.97% 49.38% 50.73% 54.63% 54.34% -
ROE 10.06% 11.12% 10.64% 9.71% 11.22% 13.29% 16.45% -
Per Share
30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 30/09/14 30/09/13 CAGR
RPS 466.02 483.20 445.75 411.83 437.45 413.34 450.39 0.56%
EPS 172.40 176.80 159.20 135.20 147.60 149.60 165.20 0.71%
DPS 52.00 52.00 52.00 52.00 52.00 52.00 52.00 0.00%
NAPS 17.13 15.88 14.91 13.87 13.15 11.26 10.04 9.30%
Adjusted Per Share Value based on latest NOSH - 1,147,516
30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 30/09/14 30/09/13 CAGR
RPS 467.47 487.56 450.75 416.46 404.18 381.93 413.42 2.06%
EPS 172.79 178.25 160.47 136.13 136.37 138.23 151.64 2.19%
DPS 52.16 52.47 52.58 52.58 48.05 48.05 47.73 1.48%
NAPS 17.1832 16.0232 15.0775 14.0258 12.1498 10.4044 9.2159 10.93%
Price Multiplier on Financial Quarter End Date
30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 30/09/14 30/09/13 CAGR
Date 30/09/19 28/09/18 29/09/17 30/09/16 30/09/15 30/09/14 30/09/13 -
Price 16.26 19.30 16.60 15.42 14.00 17.60 14.52 -
P/RPS 3.49 3.99 3.72 3.74 3.20 4.26 3.22 1.35%
P/EPS 9.44 10.92 10.46 11.45 9.49 11.76 8.79 1.19%
EY 10.59 9.15 9.56 8.73 10.54 8.50 11.38 -1.19%
DY 3.20 2.69 3.13 3.37 3.71 2.95 3.58 -1.85%
P/NAPS 0.95 1.22 1.11 1.11 1.06 1.56 1.45 -6.80%
Price Multiplier on Announcement Date
30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 30/09/14 30/09/13 CAGR
Date 27/11/19 28/11/18 30/11/17 22/11/16 17/11/15 25/11/14 26/11/13 -
Price 16.76 19.18 16.06 15.10 13.70 18.12 15.30 -
P/RPS 3.60 3.97 3.60 3.67 3.13 4.38 3.40 0.95%
P/EPS 9.73 10.86 10.12 11.22 9.28 12.11 9.26 0.82%
EY 10.28 9.21 9.88 8.92 10.77 8.26 10.80 -0.81%
DY 3.10 2.71 3.24 3.44 3.80 2.87 3.40 -1.52%
P/NAPS 0.98 1.21 1.08 1.09 1.04 1.61 1.52 -7.05%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment